IVF Hartmann Holding AG (VBSN.SW) - Deep Dive Research Report

Healthcare / Medical Consumables - SIX Swiss Exchange - Report date: 5 June 2026

Reporting-cadence note. IVF Hartmann reports twice a year and holds no quarterly earnings calls. Throughout this report, the four "reporting periods" used in place of quarterly transcripts are the two most recent full-year results (FY2024, FY2025) and the two most recent half-year results (H1 2024, H1 2025). All forward-looking statements in Sections 7 and 9 are drawn from the management commentary published with those releases.

Section 1: What the Company Does

IVF Hartmann is the Swiss arm of the German Hartmann group, and it does something deeply unglamorous and deeply durable: it makes and sells the disposable medical and hygiene products that Swiss hospitals, nursing homes, doctors' offices, pharmacies and clinics burn through every single day. Hand disinfectant. Wound dressings. Gauze. Fixation bandages. Incontinence pads. Disposable surgical sets. These are not capital purchases that a hospital agonises over once a decade - they are consumed, thrown away, and reordered next week. That reorder loop is the business.

The company sits in Neuhausen am Rheinfall, near Schaffhausen on the Rhine, employs roughly 350 people, and has been doing versions of this for over 150 years (the Swiss operation traces to 1871). It is the market reference point in Switzerland for two product categories in particular: hand disinfection, where its Sterillium brand is so dominant that Swiss healthcare workers use the brand name as a generic verb for "disinfecting your hands," and consumer wound care, where its DermaPlast plasters are a household name in Swiss pharmacies and supermarkets.

The core value proposition is reliability of supply plus regulatory trust. A hospital infection-control officer does not want to experiment with the cheapest disinfectant from an unknown importer - they want a product that is registered as a biocide/medical device in Switzerland, that the nursing staff already know how to use, and that will be on the shelf when the order is placed. IVF Hartmann supplies exactly that: a registered, locally-stocked, clinically-familiar portfolio backed by a 150-year-old name and the manufacturing and R&D weight of the wider Hartmann group behind it.

Here is the business in action. A Swiss cantonal hospital runs a standing supply arrangement covering hand disinfectant for every ward, sterile gauze and atraumatic dressings for its wound-care nurses, and incontinence pads for its geriatric unit. IVF Hartmann holds these as registered products, manufactures or imports them, warehouses them in Switzerland, and ships against the hospital's procurement system - increasingly through its Hartmann Easy digital ordering and billing platform, which also handles the reimbursement paperwork for incontinence supplies. The hospital pays for predictable availability and clinical familiarity; IVF Hartmann earns a steady, repeating consumables revenue stream. Multiply that across hospitals, the federal army's medical corps, nursing-home chains, pharmacy retailers and industrial hygiene buyers, and you have the company.

One structural fact shapes everything: IVF Hartmann is not independent. Paul Hartmann AG of Heidenheim, Germany - a roughly EUR 2.4 billion-revenue global medical group - controls the company through Paul Hartmann Finance B.V., which holds a majority stake of roughly two-thirds. IVF Hartmann is simultaneously the group's Swiss manufacturing and sales subsidiary and a separately listed public company with its own minority shareholders. That dual identity (a captive subsidiary with a public float) is the single most important thing to understand about the stock, and it threads through the customers, the economics, and the risks below.

Section 2: Business Segments

IVF Hartmann reports in four segments. Three are genuine product franchises (Wound Care, Incontinence Management, Infection Management); the fourth ("Other Group Activities") is a catch-all for adjacent consumer and logistics business. The relative scale below uses FY2024 segment sales, the last full clean year before the FY2025 mix shifts.

2.1 Infection Management (~37% of sales; the largest segment)

What it does. This is the disinfection and infection-prevention franchise, and it is anchored by Sterillium, the hand disinfectant first produced in 1965 that is effectively the category-defining brand in Switzerland. It sells hand and surface disinfectants, skin antiseptics, and risk-prevention/hygiene products into hospitals, nursing homes, medical practices, dental practices, and industrial and food-hygiene buyers. FY2024 sales were CHF 58.9 million, the biggest of the four segments, with segment EBIT of CHF 8.3 million.

Core capability. Two things are hard to replicate here. The first is regulatory: disinfectants are registered biocides and medical products, and getting a hand rub registered, formulated for skin tolerability, and clinically accepted across a national hospital system takes years and reputation. The second is the brand itself - Sterillium is the default. When a product becomes the generic name for the category in a country, a competitor has to fund both a price advantage and a clinical re-education campaign to displace it, and hospital infection-control committees are conservative by design.

Why it exists separately. Infection prevention is a different buyer (hygiene/infection-control committees and procurement) and a different regulatory regime (biocides) than wound care or incontinence. It is also the segment most exposed to demand spikes - it boomed during COVID and then normalised - so management tracks it on its own.

Competitive position. Competes against Schülke (part of Air Liquide), Ecolab, B. Braun, Bode/Hartmann group products, and Diversey in surface/industrial hygiene. In Switzerland the Sterillium franchise wins on brand entrenchment and clinical trust; it is more exposed in commoditised surface-disinfection and in price-sensitive tenders.

How it fits the group. This is the cash and scale engine - the largest revenue line and a high-recognition brand. After the post-COVID disinfection-market hangover, FY2024 and FY2025 both saw this segment recover and grow (+5.3% organic in H1 2025), which management repeatedly flagged as the bright spot offsetting weakness elsewhere.

2.2 Wound Care (~28% of sales; the volatile swing factor)

What it does. Conventional wound care - sterile gauze (Medicomp), fixation bandages (Peha-Haft), atraumatic and advanced dressings, plus the consumer first-aid plaster line. FY2024 sales were CHF 44.0 million with the highest segment EBIT of the four at CHF 10.3 million, making this the most profitable segment despite not being the largest. Critically, this segment also contains Tactical Emergency Medicine - military and emergency-services trauma products such as haemostatic dressings and emergency bandages sold to defence and security customers, often abroad.

Core capability. Standard wound care is a know-how-and-registration business: sterile manufacturing, dressing technology, and clinical positioning. The Tactical Emergency Medicine line is different - it is a specialist trauma niche selling to government and military buyers, where the capability is product specification, certification for field use, and access to defence procurement channels.

Why it exists separately. Wound care is a distinct clinical category with its own buyers (wound-care nurses, surgical departments). The Tactical Emergency Medicine sub-line is folded in here but behaves nothing like the rest: it is lumpy, order-driven government business. A single large international military order can inflate the segment in one period and its absence can deflate it the next.

Competitive position. Faces the heavyweights of global wound care: Mölnlycke, Smith & Nephew, Convatec, Coloplast, Lohmann & Rauscher, and Essity's Leukoplast/BSN brands. IVF Hartmann is a national player against multinationals here; it wins on local availability, the Hartmann brand, and the parent's dressing technology, and it loses where competitors have superior advanced-dressing R&D or deeper hospital tender relationships.

How it fits the group. This is the margin jewel and the forecasting headache. The Tactical Emergency Medicine swings are exactly why management now issues guidance excluding this product group - it distorts the picture. Wound Care fell about 12-13% in both H1 2025 and FY2025 almost entirely because the large tactical orders that boosted 2024 did not repeat.

2.3 Incontinence Management (~21% of sales; the steady grower)

What it does. Incontinence care products, led by the MoliCare brand of pads and absorbent products, sold into nursing homes, home-care, hospitals and pharmacies. FY2024 sales were CHF 33.9 million with segment EBIT of CHF 2.8 million - the lowest-margin of the three product segments. A distinguishing asset is the Hartmann Easy procurement-and-billing platform (expanded in 2023 to add a reimbursement-billing service), which digitises ordering and the Swiss insurance-reimbursement workflow for incontinence supplies.

Core capability. The product itself is relatively commoditised; the differentiation is the service wrapper. Handling the Swiss reimbursement and billing complexity for care homes and home-care patients through Hartmann Easy creates a sticky operational integration that is harder to rip out than a pad SKU.

Why it exists separately. Different end market (long-term elderly care and home care rather than acute hospital), different demand driver (demographics, not infection rates), and a different go-to-market (the digital procurement/reimbursement platform).

Competitive position. The dominant force in global incontinence is Essity's TENA brand; other competitors include Ontex and Abena. IVF Hartmann competes on the local service/billing integration and MoliCare's positioning, but it is the structural number-two-or-lower against TENA's scale.

How it fits the group. This is the demographic growth bet. It posted the strongest organic growth of any segment recently (+9.5% in H1 2025, with customer gains), riding the ageing-population tailwind. Lower margin, but the most reliable secular grower.

2.4 Other Group Activities (~14% of sales)

What it does. A residual segment: adjacent consumer health, first-aid, disposable instruments (Peha-instrument), procedure sets (MediSets), and other logistics/distribution activity that does not sit cleanly in the three core franchises. FY2024 sales CHF 22.0 million, EBIT CHF 1.6 million.

Why it exists. It is the housekeeping bucket - real revenue, modest margin, no single defining franchise. Management gives it little narrative airtime; it is neither the growth bet nor the margin engine.

Segment summary

Section 3: Products and Business Detail

The brand portfolio. IVF Hartmann sells a focused catalogue of recognised brands, several of which are group-global names it manufactures and/or distributes in Switzerland:

• Sterillium - the flagship hand disinfectant (variants include Sterillium Classic Pure, Sterillium med with higher ethanol content, Sterillium Gel, and the Protect & Care consumer line). First produced 1965; the reference brand for hand hygiene in Swiss healthcare.
• DermaPlast - consumer wound care and plasters; a household first-aid brand in Swiss pharmacies and retail.
• MoliCare - incontinence pads and absorbent products for elderly and home care.
• Medicomp - sterile gauze compresses for wound coverage.
• Peha-Haft - cohesive fixation bandages used to hold dressings in place.
• Peha-instrument - single-use disposable surgical/medical instruments.
• MediSets - pre-assembled disposable procedure/treatment sets.
• Hartmann Easy - not a product but a digital procurement and reimbursement-billing platform, central to the incontinence business.

Manufacturing and operations. The company manufactures in Switzerland at Neuhausen am Rheinfall and operates as both a producer and the Swiss sales-and-distribution hub for the wider Hartmann group's portfolio. Roughly 350 employees support production, warehousing, regulatory affairs and sales. The balance sheet is unusually conservative for a manufacturer: at end-FY2024 the company held CHF 94.9 million of cash and equivalents, an equity ratio of about 80%, and carried no financial debt - a fortress balance sheet that funds the large special dividends discussed in Section 10.

Geographies. The business is overwhelmingly Switzerland-centric for its three core consumables franchises - it is the Swiss medical-consumables supplier. The one materially international line is Tactical Emergency Medicine within Wound Care, where large orders go to foreign (defence/security) customers. That export concentration in a single volatile product group is why international sales swing the Wound Care segment so sharply year to year.

The transfer-pricing relationship. Because IVF Hartmann buys from and sells within the Hartmann group, intercompany transfer pricing materially affects reported margins. Management explicitly flagged (FY2024 release) that pricing adjustments with the parent for transfer-pricing optimisation were planned - a reminder that segment EBIT is partly an artefact of intra-group pricing, not purely arm's-length market economics.

Milestones that shaped the business. The 1965 launch of Sterillium created the franchise that still anchors the largest segment. The COVID period (2020-2022) caused a disinfection demand spike and subsequent normalisation that the company is still annualising against. The 2023 expansion of Hartmann Easy to include a reimbursement-billing service deepened the incontinence service moat. And the rise of the Tactical Emergency Medicine business turned Wound Care into both the most profitable and the most volatile segment.

Section 4: Customers

Who buys. Four broad customer types. (1) Acute care - Swiss public and cantonal hospitals and clinics buying disinfectant, wound care and disposable sets. (2) Long-term and home care - nursing homes and home-care providers buying incontinence and wound products, often via Hartmann Easy. (3) Outpatient and retail - doctors' practices, dental practices, and pharmacies (where DermaPlast and Sterillium consumer lines sell). (4) Defence and emergency services - domestic and foreign military/security buyers of Tactical Emergency Medicine, plus the Swiss army medical corps.

Who decides, and on what. In hospitals the decision sits with procurement departments and clinical committees - infection-control committees for disinfectants, wound-care specialists for dressings. Their criteria are regulatory registration, clinical familiarity, reliability of supply, and price-within-tender, roughly in that order for clinical products. The sales cycle for a standing hospital supply relationship is long and relationship-driven; for retail/pharmacy it is faster and more brand-pull driven. For Tactical Emergency Medicine the buyer is a government/defence procurement body and the cycle is project-and-tender based, which is why those orders are lumpy.

Why they choose IVF Hartmann. Specific reasons, not generic ones: Sterillium is the established standard that staff are already trained on; the products are registered Swiss medical devices/biocides held in local stock; and the company offers a service layer (Hartmann Easy reimbursement billing) that removes administrative burden from incontinence ordering. For a hospital, switching disinfectant means retraining staff and re-validating infection-control protocols - friction that favours the incumbent.

Switching costs. Moderate and category-dependent. Highest in infection management (clinical re-validation, staff retraining, committee approval) and in incontinence where Hartmann Easy is operationally embedded in a care home's billing workflow. Lowest in commoditised gauze and consumer plasters, where price and shelf availability dominate. There is no hard contractual lock-in like a multi-year equipment lease; the stickiness is operational and clinical, not legal.

Concentration and contract structure. The customer base across thousands of Swiss healthcare sites is fragmented, which is healthy. The dangerous concentration is not in the recurring base but in Tactical Emergency Medicine, where a single large international order can be a meaningful chunk of Wound Care segment revenue in a given period. Revenue is therefore a barbell: a broad, predictable, recurring consumables base (good visibility) plus a thin layer of lumpy, hard-to-forecast defence orders (poor visibility) that drives most of the year-to-year surprise.

Section 5: Competitive Landscape

This is a national champion competing against global multinationals on its home turf, segment by segment. There is no single "IVF Hartmann competitor" - there is a different opponent in each franchise.

• Infection Management: the real rivals are Schülke (Air Liquide), Ecolab, B. Braun and Diversey. IVF Hartmann wins on the Sterillium brand entrenchment and clinical trust in Switzerland; it is exposed in commoditised surface/industrial disinfection and in aggressive tender pricing.
• Wound Care: competes against the global wound-care leaders - Mölnlycke, Smith & Nephew, Convatec, Coloplast, Lohmann & Rauscher, and Essity (Leukoplast/BSN). It wins on local supply and the Hartmann name; it loses where competitors out-innovate in advanced/atraumatic dressings or out-muscle it in hospital tenders.
• Incontinence: the dominant competitor is Essity's TENA, with Ontex and Abena also present. IVF Hartmann is a challenger here, differentiating on the Hartmann Easy service wrapper rather than product superiority.

Barriers to entry - how high, really? Medium, and uneven. The barriers are (1) regulatory registration of biocides and medical devices in Switzerland, (2) clinical trust and the conservatism of infection-control committees, (3) brand equity (Sterillium, DermaPlast), and (4) the local stocking/logistics and reimbursement-billing infrastructure. These are real but not insurmountable - a determined multinational with a price advantage and a registered product can compete. What protects IVF Hartmann most is incumbency in a small, conservative market where the cost of switching a clinically-embedded product outweighs modest price savings. This is a durable niche, not an impregnable moat.

Where it is strong, where it is exposed. Strong: home-market disinfection (Sterillium), consumer wound care (DermaPlast), and the demographic-driven incontinence service model. Exposed: it is sub-scale versus every one of its multinational rivals, it depends on a German parent for product technology and pricing, and a meaningful slice of its profitability rides on a single volatile defence product line.

Section 6: Industry

Demand drivers. This is a defensive, consumption-driven industry. Demand for medical consumables tracks healthcare activity volumes (hospital admissions, procedures, outpatient visits) and, structurally, demographics - an ageing Swiss and European population mechanically increases demand for wound care and especially incontinence products over time. Infection-prevention demand is driven by hygiene standards, regulation, and episodic factors (pandemics, infection-outbreak cycles). None of these depend on the economic cycle in the way that industrials or discretionary consumer goods do - people get wounds, infections and age regardless of GDP.

Size and growth. Switzerland is a small, high-spending healthcare market; the medical-consumables niche grows at low-single-digit volumes in normal years, accelerated in specific categories by demographics (incontinence) and dampened in others by post-COVID normalisation (disinfection). The wider Hartmann group - the relevant proxy for the global industry IVF Hartmann sits inside - generated about EUR 2.4 billion in 2025 and grew low-single-digits organically, with an adjusted EBITDA margin around 11%, illustrating that this is a steady, modest-growth, modest-margin industry rather than a high-growth one.

Position in the supply chain. IVF Hartmann is a manufacturer-and-distributor: it produces in Switzerland and acts as the group's Swiss commercial hub. It sits between the group's upstream product technology/manufacturing and the downstream Swiss healthcare system, capturing the local manufacturing, registration, warehousing and distribution margin.

Regulation. The binding regulatory layer is Swiss (and EU-aligned) medical-device and biocide registration. Disinfectants are regulated biocides; wound dressings and disposable instruments are medical devices subject to conformity requirements. This regulation is the industry's primary barrier to entry and the reason incumbency matters - but it also means regulatory change (e.g. tighter MDR-style requirements) raises costs for everyone.

Cyclicality. Low. The recurring consumables base is among the most defensive revenue in healthcare. The exceptions inside IVF Hartmann are not macro-cyclical but idiosyncratic: the disinfection demand spike-and-normalisation around COVID, and the order-driven volatility of the Tactical Emergency Medicine defence business.

Tailwinds and headwinds. Tailwinds: ageing demographics (incontinence, wound care), sustained post-COVID hygiene awareness, and elevated European defence spending feeding the tactical-medicine niche. Headwinds: input-cost and procurement-cost inflation compressing margins (explicitly cited as the cause of the FY2025 profit decline), pricing pressure in commoditised categories and hospital tenders, and the lapping of elevated COVID-era disinfection demand.

Section 7: Growth Triggers

Drawn strictly from management commentary in the four reporting periods. IVF Hartmann is a low-growth defensive company, so these are modest, concrete operational items, not transformational catalysts.

• Incontinence segment momentum from customer gains. Management attributed strong incontinence growth (+9.5% organic in H1 2025) to new customer wins, and the segment continued to grow into FY2025. (H1 2025 report, 13 Aug 2025; reaffirmed FY2025 report, 3 March 2026 - repeated.)

• Infection Management / disinfection-market recovery. After the post-COVID slump, the disinfection market recovered and the Sterillium-led segment returned to growth (+5.3% organic in H1 2025), which management identified as a key offset to Wound Care weakness. (H1 2025 report, 13 Aug 2025; first flagged at FY2024, 24 Feb 2025 - repeated.)

• Continued expansion of the Tactical Emergency Medicine product group. Management stated it intends to keep expanding this product line even while warning of year-to-year order volatility. (H1 2024 report, 14 Aug 2024.)

  Management said it "intends to continue expanding its tactical emergency medicine product group," while cautioning that revenue could decline versus 2024 given the order-driven structure of the business.

• Transfer-pricing optimisation with the parent. Pricing adjustments with Paul Hartmann group for transfer-pricing optimisation were planned, a lever on intercompany margins. (FY2024 report, 24 Feb 2025.)

• FY2026 sales growth and stable EBIT guidance. For the current financial year management expects sales above the FY2025 level and EBIT roughly in line with the prior year, assuming no major market disruption and excluding the volatile Tactical Emergency Medicine swings. (FY2025 report, 3 March 2026 - new/most recent.)

  Guidance: revenues "above the level of financial year 2025" with EBIT "at the level of the previous year."

• Hartmann Easy platform as an incontinence growth/stickiness lever. The digital procurement-and-billing platform, expanded in 2023 to add reimbursement billing, underpins incontinence customer acquisition and retention. (Referenced across FY2024 and FY2025 reporting - repeated.)

Section 8: Key Risks

1. Tactical Emergency Medicine volatility distorts the most profitable segment. This is the most company-specific risk. Wound Care is the highest-EBIT segment, and a chunk of it is lumpy, order-driven defence business. When large international tactical orders land (2024) the segment surges; when they do not (2025) it falls 12-13% and drags group profit with it. The mechanism is concentration in a few large, unpredictable government orders. Management itself now guides excluding this line - an admission that it cannot be reliably forecast. High-probability moderate-to-significant drag on any given period's results.

Management excludes the Tactical Emergency Medicine business from its forward guidance precisely because of this unpredictability - a tacit acknowledgement that it is the segment's wild card.

2. Margin compression from procurement-cost inflation. FY2025 net profit fell ~10% and EBIT margin slipped from 14.5% to 13.1% explicitly because of higher procurement costs the company could not fully pass through. This is the live, realised risk - not hypothetical. As a sub-scale manufacturer buying inputs in inflationary conditions, IVF Hartmann has limited pricing power against conservative hospital tenders. High-probability moderate drag.

3. Captive-subsidiary / controlling-shareholder conflict. Paul Hartmann owns roughly two-thirds. Minority holders are along for the ride on decisions - transfer pricing, dividend policy, strategic direction - made in the parent's interest. The explicit transfer-pricing adjustments with the parent mean reported segment margins are partly a function of intercompany pricing, not pure market economics. The catastrophic-tail version is a low-balled take-private/squeeze-out of minorities. Low-probability but structurally permanent governance risk.

4. Sub-scale against global giants. In every segment IVF Hartmann is far smaller than its multinational competitors (Essity, Mölnlycke, Smith & Nephew, Schülke, Ecolab). If a major competitor decides to buy share in Switzerland on price, or out-innovates in advanced dressings, IVF Hartmann lacks the scale to respond symmetrically. Medium-probability slow-burn risk to share and margin.

5. Disinfection normalisation overhang. The Infection Management segment is annualising against elevated COVID-era hygiene demand. While it has recovered, the structural question is whether disinfection volumes settle below the inflated pandemic baseline. Moderate-probability, already partly played out.

6. Demographic concentration in a single small market. The growth engine (incontinence) and most of the business is Switzerland-only. Any adverse change to Swiss healthcare reimbursement (especially for incontinence supplies billed via Hartmann Easy) or procurement policy hits a geographically undiversified revenue base. Low-to-moderate probability, but no geographic cushion if it happens.

Section 9: Walk the Talk

The four periods used: FY2024 results (24 Feb 2025), H1 2024 (14 Aug 2024), H1 2025 (13 Aug 2025), FY2025 results (3 March 2026). The most recent is within 90 days of today. Because IVF Hartmann issues guidance in plain ranges and qualitative outlook statements rather than detailed quarterly targets, the track record is assessed against those outlook statements.

Start with H1 2024 (Aug 2024). The business was booming - sales up 6.9%, EBIT up 34.8%, margin jumping from 10.8% to 13.6%, powered by tactical-medicine deliveries to foreign customers. Crucially, management did not pretend this would continue. It explicitly warned that the Tactical Emergency Medicine line could see revenue decline versus 2024 because of how the order-driven business is structured. That was an honest, specific, falsifiable forward call.

Move to FY2024 (Feb 2025). The strong year was confirmed: sales CHF 158.8m (+7.3%), EBIT CHF 23.1m (+37.2%), a record. Management then guided FY2025 deliberately downward: EBIT "below the record year of 2024 but above the 2023 level," with sales expected to roughly match 2024 once tactical-medicine fluctuations were stripped out, and it warned of "continued volatility on procurement and sales markets."

FY2024 guidance: EBIT "below the record year of 2024, but above the 2023 level."

Now test it against H1 2025 (Aug 2025). Reality tracked the warning almost exactly. Wound Care fell 13.2%, driven "almost entirely" by absent tactical-medicine orders - precisely the risk flagged a year earlier. Group sales were roughly flat (+0.9%) and EBIT fell 9.3%, as predicted. Management reaffirmed its full-year targets despite the "challenging environment." This is the key credibility datapoint: the specific thing management warned about (tactical-order volatility) is the specific thing that happened, and they had pre-warned it twice.

Close with FY2025 (March 2026). Sales came in at CHF 161.7m (+1.8%) and EBIT at CHF 21.2m - below the 2024 record, above 2023, exactly as guided 12 months earlier. Net profit fell ~10% on higher procurement costs, which they had also flagged as a risk. The outcome landed inside the guided range. They then guided FY2026 to sales above 2025 and EBIT flat.

Assessment. This is conservative, accurate management that does what it says. The pattern across four periods is consistent: they flag risks specifically (tactical-medicine volatility, procurement-cost pressure), they guide cautiously, and outcomes land within the guided ranges. They did not over-promise during the 2024 boom - they actively tempered expectations for 2025 - and the 2025 disappointment was something they had pre-announced as a likely scenario. There is no evidence of hype, moved goalposts, or quietly dropped promises. The main caveat is that guidance is qualitative and the controlling parent shapes the numbers via transfer pricing, so "hitting guidance" is partly within the group's own control. But on the evidence available, management is credible and under-promises rather than over-promises.

Section 10: Shareholder Friendliness Index

Dividends. IVF Hartmann pays a stable ordinary dividend topped up by large special dividends funded from its substantial cash pile, and the headline total has been falling as the specials shrink. For FY2023 it paid CHF 8.20 per registered share (CHF 3.20 ordinary + CHF 5.00 special); for FY2024, CHF 6.20 (CHF 3.20 ordinary + CHF 3.00 special); and for FY2025 it proposed CHF 3.80. The ordinary component has been steady at roughly CHF 3.20, while the special distributions have been progressively reduced as earnings stepped down from the 2024 record - so the falling total reflects normalising special payouts on lower profit, not a cut to the base dividend. With a fortress balance sheet (CHF ~95m cash, ~80% equity ratio, no debt), the capacity to pay remains intact.

Buybacks and dilution. There is no meaningful buyback programme; capital return runs entirely through dividends, which makes sense given the tiny free float (the parent controls roughly two-thirds, so a buyback would shrink an already-thin float). The share count is effectively static - around 2.4 million registered shares - with no evidence of option-driven dilution or new issuance over the period. Shares are neither being created nor retired in any material amount; all the action is in the cash distribution.

Verdict: Returns Capital - a debt-free balance sheet steadily distributed to owners through a stable ordinary dividend plus sizeable (if shrinking) special dividends, with no dilution.

Section 11: Insider Activities

Venue and method. IVF Hartmann is listed on SIX; insider transactions by directors and senior management are reportable under Art. 56 of the SIX Listing Rules and disclosed through SIX Exchange Regulation's management-transactions register (ser-ag.com / the SIX disclosure portal). I made a genuine attempt to query that register for IVF Hartmann. The portal is an interactive, issuer-search disclosure database whose live results could not be retrieved within the search budget (the public page returns the database framework rather than a static, fetchable transaction list).

What the ownership structure tells us. Insiders (directors and officers) collectively hold under 1% of the company. The dominant holder is the corporate parent, Paul Hartmann (via Paul Hartmann Finance B.V.), with a controlling stake of roughly two-thirds. Changes to that controlling block would surface as significant-shareholder disclosures, not management transactions, and no change to the parent's controlling stake was reported across the period reviewed. Because the float is thin and management's personal holdings are negligible, individual director/officer open-market buying or selling is not a meaningful feature of this stock - there is little personal equity for insiders to transact in.

Net assessment. No material insider buys or sells were located for the trailing 12 months within the search budget, consistent with the structural reality that insiders own less than 1% and the company is controlled by a corporate parent rather than by individuals with large personal stakes. There is therefore no insider-transaction signal to read here - neither bullish cluster-buying nor concerning selling. This is best classified as neutral / not applicable: the absence of a signal reflects the captive-subsidiary ownership structure, not insider indifference. Insider transaction data for the SIX management-transactions register could not be fully retrieved within the search budget; the assessment above is grounded in the disclosed sub-1% insider ownership and the stable controlling-parent stake.

Section 12: Scenarios

Bull case. The defensive base does exactly what it is built to do - incontinence keeps compounding on demographics as Hartmann Easy locks in more nursing-home and home-care customers, and the Sterillium franchise holds its disinfection recovery. On top of that steady base, the Tactical Emergency Medicine line catches a sustained updraft: elevated European defence spending and security demand turn what has been lumpy into a more regular flow of large international orders, repopulating the high-margin Wound Care segment that sagged in 2025. Procurement-cost inflation eases, letting the margin drift back toward the 2024 highs. The parent keeps treating minorities fairly through generous specials funded by the debt-free balance sheet. In this world IVF Hartmann is a quietly growing, cash-generative niche compounder throwing off a reliable, occasionally fat, dividend.

Base case. The most likely path is more of the same measured progress management has guided to. Sales tick up modestly above FY2025, EBIT holds roughly flat, incontinence and infection management grow low-to-mid single digits, and Wound Care remains hostage to the timing of tactical orders - up in years they land, down in years they do not. Margins stay in the low-teens, pressured by procurement costs but defended by cost discipline and the transformation programme. The ordinary dividend stays around CHF 3.20-3.80 with special top-ups sized to the year's profit. It remains a small, stable, defensive Swiss consumables business doing what it has done for 150 years: not exciting, hard to break.

Bear case. Several specific things go wrong together. Tactical-medicine orders dry up for an extended stretch, hollowing out the most profitable segment. Procurement-cost inflation proves sticky and the company - sub-scale and facing conservative hospital tenders - cannot pass it through, so margins grind below the low-teens. A global competitor (Essity in incontinence, Schülke or Ecolab in disinfection) decides to buy Swiss share on price, and IVF Hartmann's incumbency erodes at the margin. The disinfection segment settles permanently below its COVID-inflated baseline. And the governance overhang turns concrete: the parent uses transfer pricing to shift value upstream or makes a low-balled move on the minority float. In that world the dividend specials shrink toward zero, the ordinary dividend is the only return, and the stock becomes a stagnant captive subsidiary with a structurally capped upside.

A note on the FY2025 dividend split: the company announced a total proposed dividend of CHF 3.80 for FY2025 without publicly breaking it into ordinary/special components in the sources reviewed; the chart models it as ordinary for visualisation, but treat the CHF 3.80 total as the verified figure and the split as indicative.

Sources

• IVF Hartmann FY2025 results - finanzen.ch
• IVF Hartmann FY2025 results - Moneycab
• IVF Hartmann FY2024 results (English) - Organisator
• IVF Hartmann FY2024 results - cash.ch
• IVF Hartmann H1 2025 confirms targets - finanzen.ch
• IVF Hartmann H1 2024 profit - Schaffhauser Nachrichten
• IVF Hartmann FY2023 dividend - Schaffhauser Nachrichten
• IVF Hartmann H1 2025 half-year report (PDF) - company
• IVF Hartmann FY2024 annual report (PDF) - company
• Ownership structure - Investing.com
• Products/brands - heroshygiene.ch Hartmann store
• Company profile / segments - Dun & Bradstreet
• SIX Exchange Regulation management-transactions register
• HARTMANN GROUP FY2025 (parent context) - corporate.hartmann.info

Would you like me to save this report as a .md file in the repo (I can write it to a path you specify), or save a memory note on IVF Hartmann's reporting cadence and the captive-subsidiary structure for future reference?